Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity by S. Di Mauro et al.
Liver International. 2019;00:1–13.	 	 	 | 	1wileyonlinelibrary.com/journal/liv
 
Received:	20	December	2018  |  Revised:	28	May	2019  |  Accepted:	31	May	2019
DOI: 10.1111/liv.14167  
O R I G I N A L  A R T I C L E
Serum coding and non‐coding RNAs as biomarkers of NAFLD 
and fibrosis severity
Stefania Di Mauro1 |   Alessandra Scamporrino1  |   Salvatore Petta2  |   
Francesca Urbano1 |   Agnese Filippello1 |   Marco Ragusa3,4 |   Maria T. Di Martino5 |   
Francesca Scionti5 |   Stefania Grimaudo2 |   Rosaria M. Pipitone2 |   Graziella Privitera1 |   
Antonino Di Pino1 |   Roberto Scicali1 |   Luca Valenti6  |   Paola Dongiovanni7 |   
Anna Fracanzani7  |   Agata M. Rabuazzo1 |   Antonio Craxì2 |   Michele Purrello3 |   
Francesco Purrello1 |   Salvatore Piro1
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
©	2019	The	Authors.	Liver International	Published	by	John	Wiley	&	Sons	Ltd
Stefania	Di	Mauro	and	Alessandra	Scamporrino	authors	contributed	equally	to	this	manuscript.	
Abbreviations:	ALT,	Alanine	aminotransferase;	APRI,	aspartate	aminotransferase‐to‐platelet	ratio	index;	AST,	Aspartate	aminotransferase;	AUC,	area	under	the	curve;	BMI,	body	mass	
index;	Ct,	threshold	cycle;	DE,	differentially	expressed;	FC,	fold	change;	FIB‐4,	four	factors‐based	fibrosis	index;	lncRNA,	long	non‐coding	RNA;	LSM,	liver	stiffness	measurement;	
mRNA,	messenger	RNA;	NAFL,	non‐alcoholic	fatty	liver;	NAFLD,	non‐alcoholic	fatty	liver	disease;	NAS,	NAFLD	activity	score;	NASH,	non‐alcoholic	steatohepatitis;	ncRNA,	non‐coding	
RNA;	OA,	oleate;	PA,	palmitate;	ROC,	receiver	operating	characteristics.
1Department	of	Clinical	and	Experimental	
Medicine,	Internal	Medicine,	Garibaldi‐
Nesima	Hospital,	University	of	Catania,	
Catania,	Italy
2Section	of	Gastroenterology,	
Di.Bi.M.I.S,	University	of	Palermo,	Palermo,	
Italy
3Department	of	BioMedical	Sciences	and	
BioTechnology,	Section	of	Biology	and	
Genetics	Giovanni	Sichel,	Unit	of	Molecular,	
Genome	and	Complex	Systems	BioMedicine,	
Catania,	Italy
4Oasi	Research	Institute	‐	IRCCS,	94018	
Troina,	Italy
5Department	of	Experimental	and	Clinical	
Medicine,	Magna	Graecia	University,	
Catanzaro,	Italy
6Translational	Medicine,	University	of	
Milan,	Fondazione	IRCCS	Ca'	Granda	Pad	
Marangoni,	Milan,	Italy
7Department	of	Pathophysiology	and	
Transplantation,	Section	of	Internal	
Medicine,	University	of	Milan,	Fondazione	
Ca'	Granda	IRCCS	Ospedale	Maggiore	
Policlinico,	Milan,	Italy
Abstract
Background & Aims: In	patients	with	non‐alcoholic	fatty	liver	disease	(NAFLD),	liver	
biopsy	is	the	gold	standard	to	detect	non‐alcoholic	steatohepatitis	(NASH)	and	stage	
liver	fibrosis.	We	aimed	to	identify	differentially	expressed	mRNAs	and	non‐coding	
RNAs	in	serum	samples	of	biopsy‐diagnosed	mild	and	severe	NAFLD	patients	with	
respect	to	controls	and	to	each	other.
Methods: We	 first	 performed	 a	 whole	 transcriptome	 analysis	 through	 microar‐
ray	(n	=	12:	four	Control:	CTRL;	four	mild	NAFLD:	NAS	≤	4	F0;	four	severe	NAFLD	
NAS	≥	5	F3),	followed	by	validation	of	selected	transcripts	through	real‐time	PCRs	in	
an	independent	internal	cohort	of	88	subjects	(63	NAFLD,	25	CTRL)	and	in	an	exter‐
nal	cohort	of	50	NAFLD	patients.	A	similar	analysis	was	also	performed	on	liver	bi‐
opsies	and	HepG2	cells	exposed	to	oleate:palmitate	or	only	palmitate	(cellular	model	
of	NAFL/NASH)	at	intracellular/extracellular	levels.	Transcript	correlation	with	histo‐
logical/clinical	data	was	also	analysed.
Results: We	identified	several	differentially	expressed	coding/non‐coding	RNAs	 in	
each	group	of	the	study	cohort.	We	validated	the	up‐regulation	of	UBE2V1,	BNIP3L	
mRNAs,	 RP11‐128N14.5	 lncRNA,	 TGFB2/TGFB2‐OT1	 coding/lncRNA	 in	 patients	
with	NAS	≥	5	(vs	NAS	≤	4)	and	the	up‐regulation	of	HBA2	mRNA,	TGFB2/TGFB2‐
OT1	coding/lncRNA	in	patients	with	Fibrosis	stages	=	3‐4	(vs	F	=	0‐2).	In	in	vitro	mod‐
els:	UBE2V1,	RP11‐128N14.5	and	TGFB2/TGFB2‐OT1	had	an	increasing	expression	
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1  | BACKGROUND
Non‐alcoholic	fatty	liver	disease	(NAFLD)	accounts	for	the	most	in‐
creasing	cause	of	chronic	liver	disease,	hepatocellular	carcinoma	and	
of	end‐stage	liver	disease	leading	to	liver	transplantation.1,2
Cohort	 studies	 demonstrated	 that	 among	NAFLD	populations,	
those	with	non‐alcoholic	steatohepatitis	 (NASH)	have	a	higher	risk	
of	 fibrosis	 progression,	 and	 that	 the	 presence	 of	 severe	 liver	 fi‐
brosis	 is	 the	main	driver	of	hepatic	and	extra‐hepatic	prognosis.2,3 
Even	if	 liver	biopsy	is	considered	the	diagnostic	gold	standard,	the	
availability	of	non‐invasive	markers	 to	be	used	 in	NAFLD	patients	
to	 predict	NASH	 and/or	 severity	 of	 fibrosis	 represents	 a	 relevant	
medical need.4	 To	date,	 the	diagnosis	of	NASH	 in	 clinical	 practice	
by	using	non‐invasive	scores	is	difficult	because	of	the	lack	of	well‐
performing	and	well‐validated	tools.5	Furthermore,	novel‐proposed	
NASH	blood	biomarkers,	such	as	CK18‐Asp396	fragments,	showed	
low	sensitivity	for	NASH	detection.5,6	Different	scores	are	available	
for	 the	 non‐invasive	 assessment	 of	 fibrosis	 (eg	 ‘aspartate	 amino‐
transferase	 (AST)‐to‐platelet	 ratio	 index’	 (APRI)	 and	 the	 ‘four	 fac‐
tors‐based	fibrosis	index’	(FIB‐4);	some	of	them	are	very	easy	to	use	
and	implement	in	clinical	practice	even	if	there	are	limitations	such	
as	false‐positive	results	and	high	uncertainty	areas.3,7	When	looking	
at	imaging	devices,	liver	stiffness	measurement	(LSM)	through	tran‐
sient	elastography	 (FibroScan)	 is	a	widely	diffused	 tool,	even	 if	 its	
accuracy	can	be	influenced	by	obesity	and	severity	of	steatosis.7,8
Circulating	 RNAs	 in	 plasma	 or	 serum	 have	 been	 attracting	
exponential	 attention	 as	 novel	 non‐invasive	 diagnostic	 biomark‐
ers	of	several	kinds	of	diseases.	Body	 fluid	RNAs,	 including	 long	
non‐coding	RNAs	(lncRNAs)	and	messenger	RNAs	(mRNAs),	have	
many	of	the	essential	characteristics	of	good	biomarkers,	for	ex‐
ample:	(i)	they	are	non‐invasive	accessible;	(ii)	their	levels	can	eas‐
ily	be	determined	by	basic	molecular	biology	methods,	first	of	all	
real‐time	PCR;	(iii)	they	are	remarkably	stable	in	spite	of	the	high	
amounts	of	endogenous	ribonuclease	in	body	fluids	such	as	serum	
and	plasma.9‐11
Several	 studies	 have	 highlighted	 the	 stability	 of	 lncRNAs	 and	
mRNAs,	also	under	various	experimental	and	pre‐analytical	oppres‐
sive	 conditions,	 including	 multiple	 freeze‐thaw	 cycles,	 prolonged	
incubation	 at	 room	 temperature	 (up	 to	 24h),	 exogenous	 RNAse	
treatments,	 time	 delay	 in	 processing	 of	 blood	 after	 venipuncture,	
low/high	pH.10,12‐15
The	 stability	 of	 lncRNAs	 and	 mRNAs	 in	 different	 body	 fluids	
against	endogenous	ribonuclease	degradation	may	be	provided	by	
vesicles	encapsulation	and/or	RNA	binding	protein	association	and	
also	their	highly	stable	secondary	structures.10,11,16,17
Two	 very	 recent	 studies	 reported	 the	 aberrant	 expression	 of	
long	non‐coding	RNAs	(lncRNAs)	in	liver	tissue	of	NAFL/NASH	pa‐
tients	 and	 in	mice	models	 of	NAFLD.18,19	 Furthermore,	 increasing	
trend	ranging	from	CTRL	to	oleate:palmitate	or	only	palmitate‐treated	cells	both	at	
intracellular	and	extracellular	level,	while	BNIP3L	was	up‐regulated	only	at	extracellu‐
lar	level.	UBE2V1,	RP11‐128N14.5,	TGFB2/TGFB2‐OT1	and	HBA2	up‐regulation	was	
also	observed	at	histological	 level.	UBE2V1,	RP11‐128N14.5,	BNIP3L	and	TGFB2/
TGFB2‐OT1	correlated	with	histological/biochemical	data.	Combinations	of	TGFB2/
TGFB2‐OT1	 +	 Fibrosis	 Index	 based	 on	 the	 four	 factors	 (FIB‐4)	 showed	 an	 Area	
Under	the	Curve	(AUC)	of	0.891	(P	=	3.00E‐06)	or	TGFB2/TGFB2‐OT1	+	Fibroscan	
(AUC	=	0.892,	P	=	2.00E‐06)	improved	the	detection	of	F	=	3‐4	with	respect	to	F	=	0‐2	
fibrosis	stages.
Conclusions: We	identified	specific	serum	coding/non‐coding	RNA	profiles	in	severe	
and	mild	NAFLD	patients	that	possibly	mirror	the	molecular	mechanisms	underlying	
NAFLD	progression	towards	NASH/fibrosis.	TGFB2/TGFB2‐OT1	detection	improves	
FIB‐4/Fibroscan	diagnostic	performance	for	advanced	fibrosis	discrimination.
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LAY SUMMARY
•	 Liver	biopsy	still	remains	the	gold	standard	for	NAFLD	
diagnosis	confirmation,	distinction	between	simple	stea‐
tosis	and	NASH,	and	fibrosis	staging.	No	study	has	been	
performed	regarding	the	circulating	lncRNA	and	mRNA	
signatures	as	biomarkers	in	NAFLD	patient	serum.
•	 Our	 study	 suggests	 the	use	of	 coding	 and	non‐coding	
RNA	as	non‐invasive	biomarkers	of	NAFLD	and	fibrosis	
severity.	 Combination	 of	 coding/non‐coding	 RNA	 ex‐
pression	 levels	and	clinical	data	could	be	conveniently	
applied	as	a	diagnostic	 tool	 for	non‐invasive	screening	
of	NAFLD	patients	according	to	disease	severity.
Correspondence
Francesco	Purrello,	MD,	Department	
of	Clinical	and	Experimental	Medicine,	
University	of	Catania,	U.O.	of	Internal	
Medicine,	Garibaldi	Hospital,	Via	Palermo,	
Catania,	Italy.
Email:	fpurrell@unict.it
Funding information
This	study	was	funded	by	2016/2018	
Department	Research	Plan	of	University	
of	Catania,	Department	of	Clinical	and	
Experimental	Medicine	(project	#A)	and	
by	2016/2018	Department	Research	Plan	
of	University	of	Catania,	Department	of	
Biomedical	and	Biotechnological	Sciences	
(2nd	line	of	intervention).
Handling	Editor:	Frank	Tacke
     |  3DI MAURO et Al.
experimental	evidence	is	beginning	to	characterize	the	role	of	spe‐
cific	lncRNAs	in	the	pathogenesis	of	liver	fibrosis	20	and	several	met‐
abolic	functions,	such	as	free	fatty	acid	β‐oxidation,	lipogenesis	and	
insulin	 secretion.21	 Numerous	 studies	 performed	 high‐throughput	
analysis	of	mRNAs	 in	 liver	 tissues	 from	NAFLD	patients	or	 in	vivo	
animal	models,	which	allowed	the	identification	of	several	pathways	
associated	with	disease	progression.22‐26	To	date,	no	study	has	been	
performed	on	circulating	mRNA	and	lncRNA	signatures	in	sera	from	
NAFLD	patients.	Therefore,	the	main	aim	of	this	work	was	to	analyse	
the	whole	transcriptome	profile	in	serum	samples	of	NAFLD	biopsy‐
diagnosed	patients	to	identify	novel	non‐invasive	biomarkers	which	
are	 able	 to	 identify	NAFLD	patients	with	NASH	 and/or	 advanced	
fibrosis.
2  | MATERIAL S AND METHODS
2.1 | Study subjects
This	 study	 involved	 two	subject	cohorts,	namely:	a	 first	 study	co‐
hort	recruited	in	University	Hospital	of	Palermo	which	included	71	
patients	with	biopsy‐proven	NAFLD	and	29	controls	and	a	second	
external	cohort	recruited	in	University	Hospital	of	Milan	which	in‐
cluded	50	NAFLD	patients.	A	liver	biopsy	was	performed	to	confirm	
the	diagnosis	of	NAFLD	in	patients	with	ultrasound	findings	of	fatty	
liver	and/or	persistent	(>6	months)	elevation	of	alanine	aminotrans‐
ferase	(ALT)	or	AST.	We	excluded	patients	with	alcohol‐induced	or	
drug‐induced	liver	disease	autoimmune	or	viral	hepatitis	and	chole‐
static	or	genetic	liver	disease	from	our	study.	We	also	excluded	pa‐
tients	with	current	or	past	consumption	of	ethanol	of	more	than	20	g	
per	day.	This	study	was	conducted	according	to	the	Declaration	of	
Helsinki	and	was	approved	by	the	ethics	committee	of	the	University	
Hospital	of	Palermo	and	Milan.	Before	the	procedures,	a	written	in‐
formed	consent	was	obtained	from	all	patients	participating	in	this	
study.	 Further	 information	 regarding	 histopathological	 evaluation	
and	sample	processing	can	be	found	as	Supplementary Data.
3  | RNA E X TR AC TION
We	performed	RNA	extraction	from	serum	samples	of	study	cohorts,	
from	liver	biopsies	of	12	subjects	(four	CTRL,	four	mild	NAFLD	NAS	
score	≤	4	Fibrosis	stage	=	0,	 four	severe	NAFLD	NAS	≥	5	Fibrosis	
Stage	=	3),	and	finally	from	HepG2	cells	exposed	to	lipid	treatment	
and	their	culture	media.	Total	RNA	was	extracted	by	using	miRNe‐
asy	mini	kit	(Qiagen).	Further	information	regarding	RNA	extraction	
protocol	can	be	found	as	Supplementary Data.
4  | MICROARR AY ANALYSIS
High‐throughput	 profiling	 of	 serum	 coding/non‐coding	 RNA,	
through	microarray	 technology	 by	Clariom	D	Pico	Assay	 (Thermo	
Fisher	 Scientific),	 was	 performed	 on	 12	 study	 subjects:	 four	 mild	
NAFLD	(NAS	≤	4,	Fibrosis	stage	=	0),	four	severe	NAFLD	(NAS	≥	5,	
Fibrosis	Stage	=	3)	and	four	CTRL.	Further	information	regarding	mi‐
croarray	experiments	can	be	found	as	Supplementary Data.
5  | COMPUTATIONAL ANALYSIS
To	 understand	 the	 function	 of	 statistically	 significant	 deregulated	
transcripts	 for	 each	 comparison	 (mild	 NAFLD	 vs	 CTRL,	 severe	
NAFLD	 vs	 CTRL,	 severe	 vs	mild	NAFLD),	 we	 performed	 pathway	
enrichment	 analysis	 through	 Transcriptome	 Analysis	 Console	 v.	 4	
which	 retrieves	 canonical	 biological	 pathways	 from	WikiPathways	
database	 and	 establishes	 P‐values	 using	 two‐sided	 Fisher's	 Exact	
Test	(P	<	0.05).
6  | IN VITRO CELL CULTURE 
E XPERIMENTS
Human	hepatoblastoma	cell	line	HepG2	was	cultured	as	previously	
reported.27	To	obtain	in	vitro	models	of	NAFL	or	NASH,	HepG2	at	
75%	confluence	were	exposed	 to	a	mixture	of	oleate/palmitate	or	
only	palmitate	at	a	final	fatty	acid	concentration	of	0.5	mM	for	48	h	
respectively.27 28
7  | SINGLE RE AL‐TIME PCR A SSAYS
Validation	 of	 candidate	 coding/non‐coding	 RNAs	 both	 in	 an	 in‐
dependent	 internal	 cohort	 of	 88	 study	 subjects	 (63	 NAFLD	 and	
25	 CTRL)	 and	 an	 in	 external	 cohort	 of	 50	 NAFLD	 patients	 was	
performed	 through	 real‐time	 PCR	 assays	 (Power	 SYBR	 Green	
RNA‐to‐CT1‐Step	 Kit	 Thermo	 Fisher	 Scientific)	 according	 to	 the	
manufacturer's	 protocol.	 Candidate	 transcripts	 were	 selected	 ac‐
cording	to	the	following	three	criteria:	(i)	high	levels	of	fluorescence	
microarray	signals;	(ii)	low	P‐value	in	severe	NAFLD	vs	mild	NAFLD	
comparison	 (P	 ≤	0.02);	 (iii)	 involvement	 in	oxidative	 stress,	 inflam‐
matory,	apoptotic,	authophagy	or	fibrogenic	pathways	according	to	
the	literature	data.29‐34	Validated	transcript	expression	was	also	ana‐
lysed,	through	real‐time	PCR	assays,	in	liver	biopsies	and	in	NAFL/
NASH	in	vitro	models	at	intracellular	and	extracellular	level.
7.1 | STATISTICAL ANALYSIS
Differentially	 expressed	 (DE)	 coding	 and	 non‐coding	 RNA	 identi‐
fication	 was	 performed	 by	 Transcriptome	 Analysis	 Console	 (TAC)	
Software	v.4,	according	to	the	following	parameters:	Analysis	Type:	
Expression	 Gene;	 Summarization	 Method:	 Gene	 Level	 –	 RMA;	
Gene‐Level	P	<	0.05;	ANOVA	Method:	ebayes.	GraphPad	Prism	(ver‐
sion	6.02)	was	used	to:	(i)	perform	unpaired	t	test	among	‐ΔCt	values	
obtained	after	single	real‐time	PCR	assays;	(ii)	perform	linear	regres‐
sion	analysis	between	clinical/histological	data	and	candidate	cod‐
ing/non‐coding	RNA	‐ΔCt	values.	Receiver	operating	characteristics	
4  |     DI MAURO et Al.
(ROC)	 curve	 analysis	 and	 multivariate	 logistic	 analyses	 were	 per‐
formed	through	SPSS	PASW	Statistics.
8  | RESULTS
8.1 | WHOLE TRANSCRIPTOME ANALYSIS
In	 order	 to	 identify	 novel	 potential	 biomarker	 signatures	 associ‐
ated	with	NAFLD	spectrum,	we	performed	a	whole	transcriptome	
analysis	 in	sera	 from	four	mild	NAFLD	patients	 (NAS	≤	4;	F	=	0),	
four	 severe	 NAFLD	 patients	 (NAS	 ≥	 5;	 F	 =	 3)	 and	 four	 healthy	
matched	controls.	 Statistically	 significant	deregulated	 transcripts	
in	each	comparison	are	represented	as	scatter	plots	in	Figure	1A.	
We	 identified:	 990	 deregulated	 transcripts	 in	 mild	 NAFLD	 vs	
CTRL	comparison;	1842	deregulated	transcripts	in	severe	NAFLD	
vs	CTRL	 comparison	 and	1098	deregulated	 transcripts	 in	 severe	
NAFLD	 vs	 mild	 NAFLD	 comparison.	 Fold	 change	 (FC)	 deregula‐
tion	 counts	 of	 statistically	 significant	DE	 coding	 and	 non‐coding	
RNAs	(ANOVA	Method:	ebayes	P	<	0.05)	for	each	comparison	are	
reported	 in	 Figure	 S1.	 RNA	 class	 percentage	 variations	 for	 each	
comparison	are	reported	in	Figure	S2.	Hierarchical	clustering	anal‐
ysis	of	statistically	significant	deregulated	transcripts	showed	dis‐
tinguishable	signatures	in	each	comparison:	mild	NAFLD	vs	CTRL,	
severe	NAFLD	vs	CTRL,	severe	NAFLD	vs	mild	NAFLD	(Figures	S3,	
S4	and	S5).
9  | PATHWAY ANALYSIS OF 
DIFFERENTIALLY E XPRESSED TR ANSCRIPTS
To	 explore	 the	 potential	 functions	 of	 deregulated	 transcripts,	
we	 identified	 significantly	 enriched	 biological	 pathways	 through	
Transcriptome	Analysis	Console.	This	bioinformatics	analysis	dem‐
onstrated	that	DE	transcripts	were	statistically	significant	(Fisher's	
Exact	 Test	 P	 <	 0.05)	 associated	 with	 several	 signalling	 pathways	
known	to	be	 involved	in	NASH/Fibrosis	pathogenesis	 including	 in‐
flammatory	pathways	(eg	interleukins	signalling	pathways),	metabo‐
lism	deregulation	 (eg	 electron	 transport	 chain,	 TCA	 cycle	 nutrient	
utilization,	Sterol	Responsive	Element	Binding	Protein,	insulin	signal‐
ling),	cell	death	 (eg	apoptosis,	 ferroptosis),	UPR	stress	 (eg	proteas‐
ome	degradation,	cytoplasmic	ribosomal	proteins),	and	extracellular	
matrix	biosynthesis/fibrosis	(eg	collagen	biosynthesis	and	modifying	
enzymes,	 VEGFA‐VEGFR	 signalling	 pathway,	 EGF/EGFR	 signalling	
pathway)	(Figure	1B).
10  | VALIDATION BY qPCRs
In	order	to	confirm	microarray	data,	we	analysed	the	expression	of	
candidate	transcripts	through	qPCRs	in	a	 larger	 internal	 independ‐
ent	cohort	of	88	subjects	 (CTRL	=	25	and	NAFLD	=	63)	and	 in	an	
external	 cohort	 of	 50	 NAFLD	 patients.	 Clinical	 and	 demographic	
F I G U R E  1  Scatter	plots	were	used	to	assess	the	variation	between	mild	NAFLD	vs	control	(left	panel);	severe	NAFLD	vs	CTRL	(middle	
panel);	severe	NAFLD	vs	mild	NAFLD	(right	panel)	subjects.	The	values	plotted	on	the	X	and	Y	axes	are	the	averaged	normalized	signal	
values	in	each	group	(log2	scaled).	Red	points	in	the	plot	indicate	>	2.0‐fold	up‐regulation	of	expression,	green	points	indicate	>	2.0‐fold	
down‐regulation	of	expression	and	grey	points	indicate	<	2.0‐fold	change	in	expression	(panel	A).	Enriched	Pathway	analysis.	Statistically	
significant	pathways	regulated	by	DE	transcripts	in	mild	NAFLD	vs	CTRL	comparison	(left	panel);	severe	NAFLD	vs	CTRL	comparison	(middle	
panel);	in	severe	NAFLD	vs	mild	NAFLD	comparison	(right	panel).	Values	plotted	in	X	axes	represent	‐log10	(P‐value).	Fisher's	Exact	Test	
P	<	0.05	(panel	B)
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characteristics	of	each	cohort	subjects	are	reported	in	Table	1.	We	
selected	the	following	transcripts:	HBA2,	UBE2V1,	BNIP3L	coding	
RNAs,	 RP11‐128N14.5	 lncRNA	 and	 TGFB2/TGFB2‐OT1	 coding/
non‐coding	RNA.	We	chose	these	transcripts	because:	(i)	they	pre‐
sented	high	 levels	of	 fluorescence	microarray	signals;	 (ii)	 they	pre‐
sented	a	low	P‐value	in	severe	NAFLD	vs	mild	NAFLD	comparison	
(P	 ≤	0.02);	 (iii)	 they	were	potentially	 linked	 to	oxidative	 stress,	 in‐
flammatory,	apoptotic,	authophagy	or	fibrogenic	pathways	accord‐
ing	to	literature	data.29,30,35	We	also	selected	one	ncRNA	GenBank	
ID:	AC020558.4	 (‘AceView’	database	gene	name:	 ‘sherveebu’)	as	a	
down‐regulated	control	molecule.
First,	we	grouped	the	validation	NAFLD	cohort	according	to	the	
presence	 or	 absence	 of	NASH	 (defined	 as	 simultaneous	 presence	
of	steatosis,	ballooning	and	lobular	 inflammation)	and	according	to	
Kleiner	NAS	≥	5,	associated	to	defined	NASH	diagnosis.	According	
to	microarray	results,	we	confirmed	the	up‐regulation	of	UBE2V1,	
RP11‐128N14.5,	 BNIP3L	 and	 TGFB2/TGFB2‐OT1	 in	 serum	 sam‐
ples	of	patients	with	a	NAS	≥	5	with	respect	to	those	with	NAS	≤	4	
(Figure	 2A).	 Moreover,	 taking	 into	 account	 NASH	 diagnosis	 only	
RP11‐128N14.5	reached	statistical	significance	(NOT	NASH	n	=	18	
vs		NASH	n	=	45	FC	=	7.13,	P	=	2.00E‐02)	(Figure	2B).
We	also	divided	 the	NAFLD	patient	cohort	according	 to	 fibro‐
sis	severity.	We	compared	patients	with	absent	or	mild	to	moderate	
fibrosis	 (F	=	0‐2)	with	respect	to	those	with	advanced	fibrosis	and	
cirrhosis	(F	=	3‐4).	According	to	this	classification,	we	validated	the	
up‐regulation	of	HBA2,	UBE2V1,	BNIP3L	and	TGFB2/TGFB2‐OT1.	
Therefore	HBA2	reached	statistical	significance	only	 in	F	=	3‐4	vs	
F	 =	0‐2	 comparison	 and	RP11‐128N14.5	 reached	 statistical	 signif‐
icance	only	 in	NAS	≥	5	vs	NAS	≤	4	and	NASH	vs	not	NASH	com‐
parisons	(Figure	3).	It	is	important	to	note	that,	analysed	transcripts	
were	up‐regulated	also	in	F	=	3‐4	or	NAS	≥	5	with	respect	to	control	
comparisons	as	previously	showed	in	microarray	data.	Furthermore,	
we	also	validated	AC020558.4	down‐regulation	in	NAFLD	patients	
with	respect	to	controls.	FC	values	and	P‐values	of	selected	coding/
non	coding	RNAs,	obtained	through	microarray	analysis	and	qPCRs,	
are	reported	in	Table	S1.
The	 up‐regulation	 of	 UBE2V1,	 RP11‐128N14.5,	 BNIP3L	 and	
TGFB2/TGFB2‐OT1	in	NAS	≥	5	vs	NAS	≤	4	patients,	RP11‐128N14.5	
in	 NASH	 vs	 simple	 steatosis	 and	 the	 up‐regulation	 of	 HBA2,	 and	
TGFB2/TGFB2‐OT1	 in	F	 =	3‐4	vs	F	 =	0‐2	patients	were	also	con‐
firmed	in	the	external	validation	cohort.	Transcript	FC	deregulation	
and	relative	P‐values	obtained	in	the	external	validation	cohort	are	
reported	in	Figures	S6	and	S7.
11  | VALIDATED TR ANSCRIPTS ARE 
A SSOCIATED WITH CLINIC AL MARKERS 
AND HISTOLOGIC AL SCORES
We	analysed	whether	 ‐ΔCt	values	of	validated	transcripts	were	
associated	 through	 a	 linear	 regression	 relationship	 both	 with	
the	 metabolic	 syndrome	 and	 liver	 damage‐associated	 routine	
biochemical	markers	as	with	histological	markers	used	in	clinical	
practice	to	diagnose	and	stage	NAFLD	and	fibrosis	severity	(Table	
S2).
UBE2V1	expression	levels	correlated	with	AST,	ALT,	triglycerides,	
Kleiner	ballooning	and	NAS	scores	(Figure	S8).	BNIP3L	expression	was	
directly	associated	with	Kleiner	lobular	inflammation,	ballooning	and	
fibrosis	scores	(Figure	S9).	RP11‐128N14.5	expression	was	associated	
with	 AST,	 Kleiner	 ballooning,	 NAS	 and	 fibrosis	 scores	 (Figure	 S10).	
TGFB2/TGFB2‐OT1	was	associated	through	a	positive	linear	regres‐
sion	 relationship	with	 FIB‐4,	 Liver	 Stiffness	Measurements,	 Kleiner	
lobular	inflammation	and	fibrosis	scores	(Figure	S11).	Finally,	we	found	
an	 inverse	 linear	 relationship	among	sherveebu	AC020558.4	expres‐
sion	levels	and	triglycerides	(Figure	S12)	and	between	HBA2	and	total	
cholesterol	levels.	P‐values	and	R2	values	are	reported	in	Table	S2.
12  | E XPRESSION ANALYSIS OF LIVER 
TISSUES AND IN VITRO MODEL S
In	order	 to	 further	 investigate	 the	possible	 link	between	validated	
transcripts	and	cellular/molecular	mechanisms	associated	with	dis‐
ease	evolution,	we	evaluated	whether	RNA	deregulation	observed	in	
serum	of	NAFLD	patients	was	also	present	in	liver	tissue	of	NAFLD	
patients	and	in	in	vitro	models	of	NAFL	and	NASH,	both	at	intracel‐
lular	and	extracellular	levels.	Total	RNA	was	extracted	from	liver	bi‐
opsies	of	12	subjects	(four	CTRL,	four	mild	NAFLD	NAS	≤	4	Fibrosis	
stage	=	0	and	four	severe	NAFLD	NAS	≥	5	Fibrosis	Stage	=	3).	We	
used	an	 in	vitro	model	 that	we	already	used	 in	a	previous	work.27 
HepG2	cells	were	exposed	for	48	h	to	a	mixture	of	oleate:palmitate	
(OA:PA)	 or	 only	 to	 palmitate	 (PA),	 to	 simulate	 simple	 steatosis	 or	
NASH	respectively.27
As	 shown	 in	 Figure	 4A	 in	 liver	 tissue,	 we	 observed	 a	 statisti‐
cally	 significant	 up‐regulation	 of	 UBE2V1	mRNA,	 RP11‐128N14.5	
lncRNA	 and	 TGFB2/TGFB2‐OT1	 coding/non‐coding	 RNA	 in	 se‐
vere	 NAFLD	 patients	 with	 respect	 to	 mild	 NAFLD	 patients	 and	
controls.	HBA2	resulted	 to	be	statistically	significant	up‐regulated	
only	in	severe	NAFLD	vs	CTRL	comparison.	BNIP3L	and	sherveebu 
AC020558.4	ncRNA	did	not	reach	statistical	significance	in	analysed	
liver	biopsies.	In	accordance	with	liver	tissue	data,	UBE2V1	mRNA,	
RP11‐128N14.5	 lncRNA	and	TGFB2/TGFB2‐OT1	 coding/non‐cod‐
ing	RNA	were	up‐regulated	in	cells	treated	with	PA	with	respect	to	
those	 treated	with	OA:PA	 and	 to	 controls	 (Figure	4B).	Differently	
from	 tissue	 data,	 intracellular	 HBA2	 expression	 levels	 were	 unaf‐
fected	 by	 free	 fatty	 acid	 treatments	 and	 sherveebu	 AC020558.4	
ncRNA	presented	a	statistical	significant	increasing	trend	of	expres‐
sion	ranging	from	NAFL	to	NASH	in	vitro	models.
At	 the	 extracellular	 level,	 UBE2V1	 mRNA	 and	 sherveebu 
AC020558.4	 ncRNA	 were	 statistically	 significantly	 deregulated	
only	 in	 PA	 vs	 OA:PA	 condition	 comparison;	 medium‐secreted	
RP11‐128N14.5	 lncRNA,	 BNIP3L	 mRNA	 and	 TGFB2/TGFB2‐OT1	
coding/non‐coding	RNA	were	up‐regulated	in	a	statistically	signifi‐
cant	manner	both	in	PA	vs	CTRL	comparison	as	in	PA	vs	OA:PA	com‐
parison	(Figure	4B).	Furthermore,	it	is	important	to	note	that	HBA2	
was	undetectable	in	HepG2	culture	medium.
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13  | RECEIVER OPER ATING 
CHAR AC TERISTIC S CURVE ANALYSIS
By	 performing	 ROC	 curve	 analysis,	 we	 investigated,	 the	 di‐
agnostic	 performance	 of	 validated	 transcripts	 for	 F	 =	 3‐4	 or	
NAS	 ≥	 5	 patient	 identification	 in	 NAFLD	 validation	 cohorts.	
The	 transcripts	 that	 reached	 statistical	 significance	 in	 ROC	
curve	 analysis	 were:	 (I)TGFB2/TGFB2‐OT1	 (internal	 cohort:	
AUC	 =	 0.797,	 95%	 CI	 =	 0.675‐0.918,	 sensitivity	 =	 65%,	 speci‐
ficity	=	81.3%,	P	 =	3.5E‐04;	 external	 cohort:	AUC	=	0.786,	95%	
CI	 =	 0.623‐0.950,	 sensitivity	 =	 62.5%,	 specificity	 =	 94.4%,	
P	=	4.4E‐03)	in	F	=	3‐4	vs	F	=	0‐2	comparison;	(II)	RP11‐128N14.5	
TA B L E  1  Clinical	and	demographic	data	of	internal	and	external	cohort
 
Unaffected 
controls (25)
NAFLD 
patients (63)
External cohort 
NAFLD (50)
P value 
Controls vs 
NAFLD patients
P value 
NAFLD patients vs 
external cohort
Clinical	variables
Age	(years) 48.00 ± 10.01 50.65 ± 12.35 52.76 ± 10.00 0.252 0.358
Gender	(%	of	male) 32% 59% 70% 0.043 0.298
BMI	(kg/m2) 24.14 ± 2.14 29.87 ± 4.57 29.08 ± 3.83 0.00000011 0.378
AST	(IU/I) 20.63 ± 5.81 46.50 ± 27.77 41.10 ± 29.03 0.00002 0.348
ALT	(IU/I) 20.71 ± 7.21 78.03 ± 67.09 57.44 ± 46.45 0.0001 0.091
Platelets	(×109/I) 248.50 ± 36.96 236.18 ± 87.44 202 ± 72.38 0.234 0.063
Total	cholesterol	(mg/dL) 200.94 ± 39.90 191.42 ± 39.74 186.39 ± 41.58 0.387 0.556
HDL	cholesterol	(mg/dL) 61.50 ± 10.17 48.54 ± 16.44 46.18 ± 14.31 0.035 0.460
Triglycerides	(mg/dL) 93.88 ± 30.27 136.93 ± 74.29 154.90 ± 70.63 0.023 0.231
FIB‐4	score  1.52 ± 1.36 1.61 ± 0.96  0.756
APRI	score  0.38 ± 0.35 0.59 ± 0.58  0.036
LSM	–	KPa  12.27 ± 11.90    
Histology
Kleiner	steatosis	grade	(0‐3)
0  ‐ 1	(2%)  0.352
1  19	(30%) 11	(22%)  
2  24	(38%) 17	(34%)  
3  29	(46%) 21	(42%)  
Kleiner	lobular	inflammation	score	(0‐3)
0  ‐‐‐ 3	(6%)  0.550
1  37	(59%) 15	(30%)  
2  21(33%) 27	(54%)  
3  5	(8%) 5	(10%)  
Kleiner	Ballooning	score	(0‐2)
0  18	(29%) 16	(32%)  0.510
1  33	(52%) 27	(54%)  
2  12	(19%) 7	(14%)  
Kleiner	NAS		(0‐8)
≤4  38	(60%) 23	(46%)  0.598
≥5  25	(40%) 27	(54%)  
Kleiner	fibrosis	stage	(0‐4)
0‐2  37	(59%) 26	(52%)  0.275
3‐4  26	(41%) 24	(48%)  
Clinical	and	demographic	indicators	were	checked	for	significant	differences	by	t	test	or	Mann‐Whitney	U‐test,	respectively	for	normally	distributed	
or	not	normally	distributed	variables.	The	Chi‐square	test	was	used	for	categorical	variables.	The	continuous	normally	distributed	variables	were	
represented	as	mean	±	SD	categorical	and	non‐normal	variables	were	summarized	as	median	and	percentage.
The	bold	values	are	significance.
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F I G U R E  2  Fold	Change	of	UBE2V1	
mRNA,	RP11‐128N14.5	lncRNA,	BNIP3L	
mRNA,	TGFB2/TGFB2‐OT1	coding/
lncRNA	validated	through	real‐time	PCRs	
in	serum	samples	of	patients	with	NAS	
score	≤	4	or	NAS	score	≥	5	respect	to	
healthy	controls	(panel	A).	Fold	Change	
of	RP11‐128N14.5	lncRNA	validated	
through	real‐time	PCRs	in	serum	samples	
of	patients	with	simple	steatosis	or	
defined	NASH	respect	to	healthy	controls	
(panel	B).	n =	88:25	CTRL,	38	NAS	≤	4,	25	
NAS	≥	5.18	NOT	NASH,	45	NASH.	t	test	
*P	≤	0.05,**P ≤	0.02
F I G U R E  3  Fold	Change	of	HBA2	
mRNA,	UBE2V1	mRNA,	BNIP3L	
mRNA,	TGFB2/TGFB2‐OT1	coding/	
lncRNA	validated	through	real‐time	
PCRs	in	serum	samples	patients	with	
Fibrosis	Stages	F	=	0‐2	or	F	=	3‐4	
respect	to	healthy	controls.	n =	88:25	
CTRL,	37	F	=	0‐2,	26	F	=	3‐4.	t	test	
*P ≤	0.05,**P	≤	0.01,***P	≤	0.001
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F I G U R E  4  Histograms	of	coding/noncoding	RNA	expression	levels	observed	in	liver	biopsies	(n	=	12,	four	CTRL,	four	mild	NAFLD:	
NAS	≤	4	F	=	0,	four	severe	NAFLD	NAS	SCORE	≥	5	F	=	3)	(panel	A)	and	in	OA:PA	and	PA	treated	HepG2	with	respect	to	controls	at	
intracellular	and	extracellular	levels	(panel	B).	OA:PA	=	oleate:palmitate;	PA	=	palmitate;	CTRL	=	control.	FC	=	fold	change
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(internal	 cohort:	 AUC	 =	 0.706,	 95%	 CI	 =	 0.554‐0.857,	 sensitiv‐
ity	 =	 73.7%,	 specificity	 =	 70.4%,	 P	 =	 1.9E‐02;	 external	 cohort:	
AUC	=	0.694,	95%	CI	=	0.545‐0.843,	sensitivity	=	78.3%,	specific‐
ity	=	63%,	P	=	2.0E02)	and	BNIP3L	(internal	cohort:	AUC	=	0.676,	
95%	 CI	 =	 0.512‐0.841,	 sensitivity	 =	 57.9%,	 specificity	 =	 81.5%,	
P	=	4.3E‐02;	external	cohort:	AUC	=	0.686,	95%	CI	=	0.537‐0.835,	
sensitivity	=	51.9%,	specificity	=	91.3%,	P	=	3.0E02)	in	NAS	≥	5	vs	
NAS	≤	4	comparison.
It	 is	 important	 to	 note	 that	 TGFB2/TGFB2‐OT1	 expression	
levels	were	associated	with	the	blood‐based	 index	FIB‐4	and	LSM	
used	in	clinical	practice	for	non‐invasive	diagnosis	of	F	=	3‐4	stages	
and	 histological	 Kleiner	 fibrosis	 stage.	 Comparison	 of	 the	 AUCs	
revealed	 the	 combinations	 TGFB2/TGFB2‐OT1	 plus	 FIB‐4	 (inter‐
nal	cohort:	AUC	=	0.891,	95%	CI	=	0.799‐0.982,	sensitivity	=	80%,	
specificity	 =	 87.5%,	 P	 =	 3.0E‐06;	 external	 cohort:	 AUC	 =	 0.889,	
95%	 CI	 =	 0.771‐0.998,	 sensitivity	 =	 87.5%,	 specificity	 =	 83.3%,	
P	 =	 1.1E‐04)	 or	 TGFB2/TGFB2‐OT1	 plus	 LSM	 (AUC	 =	 0.892,	
95%	 CI	 =	 0.802‐0.983,	 sensitivity	 =	 80%,	 specificity	 =	 90.6%,	
P	=	2.0E‐06)	were	superior	to	APRI	 (internal	cohort:	AUC	=	0.759,	
95%	 CI	 =	 0.626‐0.893,	 sensitivity	 =	 55%,	 specificity	 =	 93.8%,	
P	=	1.8E‐0.3;	external	cohort:	AUC	=	0.667,	95%	CI	=	0.479‐0.854,	
sensitivity	=	68.8%,	specificity	=	66.7%,	P	=	9.8E‐02);	FIB‐4	(inter‐
nal	cohort:	AUC	=	0.819,	95%	CI	=	0.700‐0.937,	sensitivity	=	60%,	
specificity	 =	 93.8%,	 P	 =	 1.3E‐0.4;	 external	 cohort:	 AUC	 =	 0.839,	
95%	 CI	 =	 0.698‐0.979,	 sensitivity	 =	 93.8%,	 specificity	 =	 66.7%,	
P	=	7.7E‐04);	TGB2/TGFB2‐OT1	(internal	cohort:	AUC	=	0.797,	95%	
CI	=	0.675‐0.918,	sensitivity	=	65%,	specificity	=	81.3%,	P	=	3.5E‐04;	
external	 cohort:	 AUC	 =	 0.786,	 95%	 CI	 =	 0.623‐0.950,	 sensitiv‐
ity	=	62.5%,	specificity	=	94.4%,	P	=	4.4E‐03)	and	LSM	(AUC	=	0.841,	
95%	 CI	 =	 0.723	 −0.960,	 sensitivity	 =	 85%,	 specificity	 =	 81.3%,	
P	=	4.0E‐05)	(Figure	5,	Figure	S13).
In	 NAS	 ≥	 5	 patient	 discrimination,	 RP11‐128N14.5	 diagnostic	
performance	was	comparable	or	superior	to	AST	performance	(inter‐
nal	cohort:	AUC	=	0.707,	95%	CI	=	0.554‐0.860	sensitivity	=	73.7%,	
specificity	=	74.1%,	P	=	1.8E‐02;	external	cohort:	AUC	=	0.659,	95%	
CI	=	0.470‐0.849,	sensitivity	=	38.9,	specificity	=	99%,	P	=	8.3E02)	and	
superior	to	ALT	(internal	cohort:	AUC	=	0.367,	95%	CI	=	0.203‐0.532,	
sensitivity	=	94.7%,	specificity	=	3.7%,	P	=	1.3E‐01;	external	cohort:	
AUC	=	0.633,	95%	CI	=	0.449‐0.817,	 sensitivity	=	55.6%,	specific‐
ity	=	82.6%,	P	=	1.5E01).	Combination	of	RP11‐128N14.5	with	AST	
or	ALT	did	not	improve	its	diagnostic	performance.
In	 NASH	 vs	 not	 NASH	 comparison,	 RP11‐128N14.5	 did	 not	
reach	 statistical	 significance;	 however,	 its	 AUC	 (internal	 cohort:	
AUC	 =	 0.632,	 95%	 CI	 =	 0.477‐0.787,	 sensitivity	 =	 86.7%,	 spec‐
ificity	 =	 38.9%,	 P	 =	 1.0E‐01;	 external	 cohort:	 AUC	 =	 0.650,	
95%	 CI	 =	 0.480‐0.819,	 sensitivity	 =	 53.3%,	 specificity	 =	 4.3%,	
P	 =	 9.7E‐02)	 was	 superior	 with	 respect	 to	 ALT	 (internal	 cohort:	
AUC	 =	 0.412,	 95%	 CI	 =	 0.258‐0.567,	 sensitivity	 =	 25%,	 spec‐
ificity	 =	 83.3%.	 P	 =	 2.9E‐01,	 external	 cohort:	 AUC	 =	 0.567,	
95%	 CI	 =	 0.390‐0.744,	 sensitivity	 =	 57.7%,	 specificity=73.3%,	
P	=	4.8E‐01)	and	similar	to	AST	(AUC	=	0.558,	95%	CI	=	0.397‐0.720,	
sensitivity	=	69.2%,	specificity	=	55.6%,	P	=	4.8E‐01;	external	co‐
hort	 AUC	 =	 0.672,	 95%	 CI	 =	 0.503‐0.842,	 sensitivity	 =	 62.5%,	
specificity	 =	 80%;	P	 =	 7.3E‐02).	 Combination	 of	 RP11‐128N14.5	
with	AST	or	ALT	in	both	cohorts	decreased	its	AUC:	0.5	P	=	1.
14  | DISCUSSION
In	 this	 multiphase	 case‐control	 study,	 we	 performed	 an	 initial	
screening	of	coding	mRNAs	and	ncRNAs	in	biopsy‐proven	NAFLD	
patients	at	different	stages	of	histopathological	severity	and	con‐
trols	(n	=	12:	4	CTRL,	4	NAS	≤	4	F	=	0,	4	NAS	≥	5	F	=	3).	Interestingly,	
performing	computational	analysis,	we	observed	that	deregulated	
transcripts,	resulting	from	this	initial	screening,	resulted	to	be	sta‐
tistically	associated	to	key	pathways	known	to	be	involved	in	fibro‐
sis	and	NASH	physiopathogenesis	such	as	inflammation,	UPR	stress	
and	metabolism.	To	better	characterize	our	results,	we	chose,	for	
subsequent	qPCR	validation,	five	DE	transcripts	in	severe	NAFLD	
vs	mild	NAFLD	with	a	very	compelling	P‐value	(≤	0.02)	and	poten‐
tially	 linked	 to	 NASH	 progression	 and	 fibrogenic	 pathways.	 The	
potential	 of	 validated	 transcripts	 for	 predicting	 disease	 severity	
(NAS	 ≥	 5)	 or	 advanced	 fibrosis	 (F	 =	 3‐4)	 in	NAFLD	 patients	was	
also	evaluated.	Interestingly,	combinations	of	TGFB2/TGFB2‐OT1	
plus	FIB‐4	(AUC	=	0.891,	P	=	3.00E‐06)	or	TGFB2/TGFB2‐OT1	plus	
LSM	(AUC	=	0.892,	P	=	2.00E‐06)	were	able	to	powerfully	discrimi‐
nate	patients	with	F	3‐4	with	respect	to	patients	F	0‐2.	Therefore,	
the	combination	of	coding/non‐coding	RNA	expression	values	and	
routine	clinical	data	could	be	conveniently	applied	as	a	diagnostic	
tool	for	non‐invasive	screening	of	NAFLD	patients	according	to	fi‐
brosis	stage.	Moreover,	the	best‐performing	transcript	for	NAS	≥	5	
patient	identification,	RP11‐128N14.5,	achieved	an	AUC	similar	to	
AST,	and	their	combined	use	did	not	improve	the	diagnostic	power.	
Therefore,	the	identification	of	novel	NASH	diagnosis	biomarkers	
is	still	open	and	needs	to	be	addressed.
In	order	to	determine	a	possible	link	between	selected	coding/
non‐coding	RNAs	and	synergic	and	complex	mechanisms	underlying	
disease	and	fibrosis	progression,	we	tested	the	hypothesis	of	a	sta‐
tistical	association	between	validated	transcript	expression	and	his‐
tological	features	of	NAFLD	spectrum.	In	our	study,	we	observed	that	
UBE2V1,	 BNIP3L,	 RP11‐128N14.5,	 TGFB2/TGFB2‐OT1	were	 cor‐
related	with	Kleiner	histological	scores:	Kleiner	NAS	correlated	with	
UBE2V1	(P	=	4.0E‐03)	and	RP11‐128N14.5	 (P	=	3.10E‐02);	Kleiner	
lobular	 inflammation	score	correlated	with	BNIP3L	 (P	=	8.00E‐03)	
and	 TGFB2/TGFB2‐OT1	 (P	 =	 3.10E‐02);	 Kleiner	 ballooning	 score	
correlated	 with	 UBE2V1	 (P	 =	 4.50E‐02),	 BNIP3L	 (P	 =	 2.60E‐02),	
RP11‐128N14.5	 (P	 =	 1.20E‐02);	 Kleiner	 fibrosis	 score	 correlated	
with	 BNIP3L	 (P	 =	 3.60E‐02),	 RP11‐128N14.5	 (P	 =	 3.70E‐02)	 and	
TGFB2/TGFB2‐OT1	(P	=	1.60E‐02).	The	statistical	correlation	with	
histological	scores	of	disease	severity	and	fibrosis	stages	suggests	
that	analysed	transcripts	could	be	potentially	associated	with	NASH	
and	hepatic	fibrogenesis	molecular	features.
Explaining	the	relationship	between	RNA	extracellular	expression	
and	affected	tissues	is	a	difficult	challenge.	We	tried	to	respond	to	this	
question	by	verifying	whether	RNA	deregulation	in	patients	could	be	
somehow	mirrored	in	liver	tissue	of	NAFLD	subjects	and	into	in	vitro	
models	of	NAFLD	disease,	both	at	intracellular	and	extracellular	levels.
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María	José	Gómez‐Lechón	et al,36	and	also	our	research	group,27 
validated	differential	 in	vitro	models	of	NAFL	and	NASH.	More	 in	
detail,	we	treated	HepG2	cells	with	an	oleate/palmitate	mixture	or	
only	palmitate	in	order	to	mimic	NAFL	or	NASH	respectively.
Interestingly,	 switching	 from	 control	 conditions	 to	 OA:PA	 and	
PA‐treated	 cells,	 the	RNAs	 secreted	 into	 the	medium	partially	 re‐
flected	 the	 expression	 trends	 observed	 in	 serum	 samples	 from	
healthy	controls	and	mild	and	severe	NAFLD	patients.	In	our	in	vitro	
model,	we	also	found	that	the	cellular	expression	of	mRNA	UBE2V1,	
lncRNA	 RP11‐128N14.5,	 ncRNA	 sherveebu	 AC020558.4,	 TGFB2/
TGFB2‐OT1	 coding/non‐coding	 RNA	 progressively	 increased,	
switching	 from	CTRL	 to	OA:PA	and	PA	 conditions.	 Saturated	 free	
fatty	acid	palmitate,	which	is	mainly	responsible	for	lipotoxic	effects	
compared	to	unsaturated	fatty	acid	oleate,	seems	to	trigger	an	 in‐
duction	 of	 UBE2V1	 mRNA,	 RP11‐128N14.5	 lncRNA	 and	 TGFB2/
TGFB2‐OT1	expression.	Deregulation	of	previous	validated	coding/
non‐coding	RNA	in	our	in	vitro	models,	further	supports	the	statisti‐
cally	significant	association	between	analysed	transcripts	in	patient	
sera	 and	 clinical	 histological	 scores	 of	 disease	 severity,	 and	 paves	
the	way	to	explore	the	potential	involvement	of	analysed	RNA	mol‐
ecules	in	molecular	pathways	of	disease	evolution	through	transient	
or	permanent	inhibition	methodology,	especially	for	ncRNAs,	whose	
function	 and	 involvement	 in	 NAFLD	 spectrum	 have	 not	 yet	 been	
characterized.
NASH	affects	not	only	hepatocytes	 in	 the	 liver,	but	 it	 involves	
several	 other	 hepatic	 cell	 types	 (eg	 Hepatic	 Stellate	 Cells,	 innate	
immune	 liver	 cells:	Kupffer	 cells,	 natural	 killer	 cells)	 and	other	 tis‐
sues/organs	 (eg	gut,	adipose	tissue,	circulating	 inflammatory	cells);	
therefore	 analysed	 transcript	 deregulation	 in	 cellular	 models	 of	
NAFL/NASH	 represents	 only	 an	 attempt	 to	 explain	 the	 increased	
serum	lncRNA/mRNA	levels	which	could	arise	from	others	hepatic	
cells,	extra‐hepatic	tissues,	or	as	a	result	of	cumulative	effects.	To	get	
further	insight	on	the	potential	liver	origin	of	deregulated	transcripts	
and	 the	 relationship	 among	 them	 and	 biological/molecular	 mech‐
anisms	 underlying	NASH/Fibrosis	 severity,	we	 analysed	 transcript	
expression	in	liver	biopsies	of	NAFLD	patients	and	healthy	controls.	
Interestingly	 UBE2V1,	 RP11‐128N14.5,	 TGFB2/TGFB2‐OT1	 were	
up‐regulated	in	severe	NAFLD	patient	with	respect	to	mild	NAFLD	
and	controls.	HBA2	was	up‐regulated	only	in	severe	NAFLD	patient	
vs	controls.
A	 link	 between	haemoglobin	 levels	 and	NASH	already	 exists.	
Akyuz	et al	reported	that	increased	serum	haemoglobin	is	the	only	
independent	predictor	of	both	NASH	and	hepatic	fibrosis	in	NAFLD	
patients	with	BMI	<	25	kg/m2.37	Trak‐Smayra	and	colleagues	per‐
formed	a	proteomic	study	in	a	cohort	of	obese	patients	in	the	pres‐
ence	or	absence	of	liver	lesions:	they	observed	an	increase	of	free	
haemoglobin	 subunits	 ranging	 from	 obese	 patients	 without	 liver	
lesion	to	those	with	simple	steatosis	and	then	to	NASH,	which	re‐
turned	to	normal	values	after	weight	loss.38	Whether	increased	free	
serum	haemoglobin	subunits	is	owing	to	the	increased	hemolysis	or	
increased	 gene	 and	 protein	 expression	 occurring	 in	 the	 affected	
liver,	needs	to	be	elucidated.	 In	support	of	the	first	hypothesis,	 it	
has	been	reported	that	oxidative	stress	induces	an	increased	eryth‐
rocyte	 susceptibility	 to	 haemolysis	 in	 animal	models	 of	NASH	 30 
and	 in	obese	subjects.39	 In	support	of	the	second	hypothesis,	Liu	
et al	 reported	an	 increased	expression	of	HBA1	and	HBB	 in	 liver	
F I G U R E  5  Univariate	and	Multivariate	ROC	curve	analysis	for	predicting	APRI,	FIB‐4,	LSM,	TGFB2/TGFB2‐OT1,	TGFB2/TGFB2‐
OT1	+	FIB‐4,	TGFB2	+	Fibroscan	as	F	=	3‐4	patient	diagnosis	biomarkers	with	respect	to	F	=	0‐2	patients.	APRI	AUC	=	0.759	(95%	
CI	=	0.626‐0.893	sensitivity	=	55%,	specificity	=	93.8%,	P	=	1.80E‐03);	FIB‐4	AUC	=	0.819	(95%	CI	=	0.700‐0.937	sensitivity	=	60%,	
specificity	=	93.8%,	P	=	1.30E‐04);	TGFB2/TFB2‐OT1	AUC	=	0.797	(95%,	CI	=	0.675‐0.918	sensitivity	=	65%,	specificity	=	81.3%,	
P	=	3.50E‐04);	TGFB2/TGFB2‐OT1	+	FIB4	AUC	=	0.891	(95%	CI	=	0.799‐0.982,	sensitivity	=	80%,	specificity	=	87.5%,	P	=	3.00E‐06).	
TGFB2/TFB2‐OT1	+	Fibroscan	AUC	=	0.892	(95%	CI	=	0.802‐0.983	sensitivity	=	80%,	specificity	=	90.6%,	P	=	2.00E‐06)
TGFB2/TGFB2 - OT1 + FIBROSCAN
TGFB2/TGFB2 - OT1 
FIB-4
APRI
FIBROSCAN
TGFB2/TGFB2 - OT1 + FIB-4
AUC TGFB2/TGFB2 – OT1: 0,797
AUC FIB-4: 0,819
AUC APRI: 0,759
AUC FIBROSCAN: 0,841    
AUC TGFB2/TGFB2 – OT1 + FIB-4: 0,891
AUC TGFB2/TGFB2 – OT1 + FIBROSCAN: 0,892
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biopsies	 of	 NASH	 patients	 with	 respect	 to	 controls.	 They	 also	
demonstrated	that	H2O2 treatment	of	HepG2	cells	increases	gene	
and	 protein	 expression	 of	HBA1	 and	HBB.	 Furthermore,	 haemo‐
globin	over‐expression	induced	oxidative	stress	decrease.29 In ac‐
cordance	with	these	results	we	observed	a	statistically	significant	
up‐regulation	of	HBA2	transcript	in	severe	NAFLD	patients	respect	
to	 controls.	However,	 despite	 the	 fact	 that	 palmitate	 is	 a	 known	
oxidative	stress	inducer,40	we	did	not	observe	any	HBA2	gene	ex‐
pression	alteration	in	our	in	vitro	models	and	we	were	not	able	to	
detect	HBA2	expression	 in	 culture	medium.	Probably,	 in	NAFLD,	
the	main	contribution	of	the	increase	in	HBA2	gene	expression	is	
given	 by	 other	 cell	 types,	 different	 from	 hepatocytes,	 inside	 the	
affected	liver	tissue.
Although	 any	 direct	 link	 among	UBE2V1	 gene	 expression	 and	
NAFLD	has	not	been	reported,	UBE2V1	is	involved	in	non‐canonical	
IKK	 poly‐ubiquitination,	 which	 in	 turn	 activates	 NF‐kappa‐B	 cas‐
cade,	which	is	one	of	the	key	pro‐inflammatory	signalling	pathways	
active	in	NASH.41
There	are	not	any	literature	data	concerning	the	involvement	of	
RP11‐128N14.5	 in	NAFLD.	RP11‐128N14.5	 is	 a	 long	 intronic	RNA	
transcribed	 in	 the	 same	 direction	 of	 its	 protein‐coding	 host	 gene	
RAP2A.	RP11‐128N14.5,	 as	already	 reported	 for	 several	 lncRNAs,	
could	have	a	role	in	the	epigenetic	regulation	of	its	host	gene	locus.	
There	are	no	published	data	on	the	association	between	the	RAP2A	
coding	 gene	 and	NAFLD	 spectrum;	 however,	 it	 has	 been	 reported	
that	in	hepatocellular	carcinoma,	RAP2A	regulates	MAP4K4,	which	
leads	to	JNK	and	NF‐κB	signalling	activation	which	are	the	members	
of	common	molecular	pathways	of	NASH	pathogenesis.
TGF‐β	is	a	homodimer	that	exists	in	three	different	isoforms	(‐β1,	
‐β2	and	‐β3)	in	mammals	and	all	TGF‐β	ligands	act	through	the	same	
receptor	signalling	systems.	 It	has	been	widely	demonstrated	that,	
in	 the	 liver,	TGF‐β	 signalling	 is	 involved	 in	 the	 fibrogenic	 response	
through	hepatic	stellate	cell	activation.	Furthermore,	it	has	been	re‐
ported	that	TGF‐β	signalling	in	hepatocytes	contributes	to	hepato‐
cyte	death	and	lipid	accumulation	that	promote	the	development	of	
NASH.42	In	real‐time	validation	experiments,	we	used	primers	able	
to	 amplify	 both	 mRNA	 encoding	 for	 TGFB2	 and	 lncRNA	 TGFB2‐
Overlapping	Transcript	1,	a	newly	discovered	lncRNA	deriving	from	
the	3'‐UTR	of	TGFB2.	We	found	that	levels	of	TGFB2/TGFB2‐OT1	
were	highly	increased	in	serum	samples	of	patients	with	a	NAS	≥	5	
and	fibrosis	F	=	3‐4.
Several	studies	have	highlighted	the	role	of	TGFB2‐OT1	 in	 the	
regulation	 of	 autophagy,	 apoptotic,	 inflammatory	 and	 fibrogenic	
pathways,	all	known	to	be	involved	in	NAFLD	progression.43	It	has	
been	reported	that	TGFB2‐OT1	is	involved	in	the	negative	regulation	
of	apoptosis	and	positive	regulation	of	autophagy	and	inflammation	
in	vascular	endothelial	 cells.31,44	Long	Xiang	Tu	and	colleagues	 re‐
ported	the	up‐regulation	of	TGFB2‐OT1	in	fibroblasts	derived	from	
hypertrophic	 scars,	 suggesting	 its	 involvement	 in	 excessive	 prolif‐
eration	of	fibroblasts	and	accumulation	of	extracellular	matrix.45	As	
concerns	TGFB2,	its	pro‐fibrogenic	role	and/or	its	increased	gene	or	
protein	expression	has	been	reported	in	lens	fibrosis,	kidney	fibrosis,	
cardiac	fibrosis	and	liver	fibrosis.46
Several	studies	reported	the	involvement	of	BNIP3L	in	the	regu‐
lation	of	pathways	associated	with	NASH	pathogenesis,	specifically,	
apoptosis,	necrosis,	autophagy	and	fibrosis.	Several	studies	supported	
BNIP3L	 involvement	 in	apoptosis	and	necrosis	of	 cardiomyocyte	 in	
heart	diseases.47	HIF1b‐dependent	BNIP3L	increased	gene	and	pro‐
tein	expression	has	been	 reported	 in	primary	cultured	hepatocytes	
exposed	to	ethanol	and	in	mice	models	of	alcohol‐induced	liver	injury	
and	steatosis.48	Although	these	data	support	the	potential	activation	
of	this	pathway	in	liver	steatosis,	we	did	not	observe	its	activation	in	
liver	biopsies	and	 in	 in	vitro	model	at	 intracellular	 level.	Concerning	
the	pro‐fibrogenic	role	of	BNIP3L,	Weili	Liu	and	colleagues	reported	
that	the	expression	of	BNIP3L	is	increased	in	cardiac	fibrosis.32
Although	the	major	limitation	of	our	study	is	the	small	sample	
size,	our	results	may	contribute	to	increase	the	understanding	of	
NAFLD	physiopathology.	Our	 qPCR	 results,	 or	 other	 results	 de‐
riving	from	microarray	analysis	or	from	similar	studies,	need	to	be	
validated	in	larger	patient	cohorts	with	a	clearer	stratification	ac‐
cording	to	NAS	(NAS	≤	3	vs	NAS	≥	5).	Serum	RNAs	should	be	ana‐
lysed	in	in	vivo	animal	models	in	which	genetic	and	environmental	
confounding	 effects	 should	 be	 minimized.	 Finally,	 intracellular	
RNAs	should	be	assessed	in	liver	biopsies	of	larger	patient	cohort.	
Notwithstanding	these	limitations,	our	data	contribute	to	expand	
the	knowledge	on	molecular	mechanisms	associated	with	NAFLD	
pathophysiology.	Moreover,	 they	could	provide	 the	evidence	 for	
identification	of	novel	biomarkers	as	 future	possible	alternatives	
to	liver	biopsy.
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